Lilly Reassumes Sole Worldwide Development and Commercialization Rights for Novel Basal Insulin Analog

General Press Releases Tuesday January 8, 2013 08:48
INDIANAPOLIS and INGELHEIM, Germany--8 Jan--PRNewswire/InfoQuest
  • Announces it will begin remainder of pre-planned clinical trials for LY2605541

Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim International GmbH announced today they will adjust the scope of their diabetes alliance with respect to LY2605541*, Lilly's novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541.

Lilly and Boehringer Ingelheim formed their diabetes alliance in January 2011, centering on four pipeline compounds representing several of the largest and most promising product classes. It is one of the largest alliances among two pharmaceuticals companies ever in a single therapeutic area and aims to provide a broad portfolio of treatment options for patients with diabetes and their healthcare professionals.

While Lilly and Boehringer Ingelheim will continue to jointly develop and commercialize the other assets in the alliance, Boehringer Ingelheim elected to terminate the collaboration with Lilly with respect to LY2605541 given independent strategic portfolio considerations.

"There is an excellent spirit of collaboration in our alliance with Lilly, and we are committed to the continued success in our partnership to develop and commercialize the other molecules within the alliance, including Trajenta(R) (linagliptin), empagliflozin and LY2963016, new insulin glargine product," said Dr. Ulrich Drees, Corporate Senior Vice President, International Project Management at Boehringer Ingelheim.

Lilly also announced plans for the 2013 and 2014 initiation of the remainder of the pre-planned clinical trials for LY2605541. In addition to supporting regulatory submissions, these studies will be conducted to evaluate safety, efficacy and differentiation of this novel basal insulin analog. These studies are in addition to the five ongoing IMAGINE clinical trials.

"We're encouraged by the pre-clinical, Phase I and II data we've seen for our novel basal insulin," said Gwen Krivi, Ph.D, vice president, Diabetes Product Development, Lilly Diabetes.   "We look forward to sharing the Phase III data results of our novel basal insulin therapy with the medical community as early as 2014."

"Boehringer Ingelheim is an important partner in our strategy to provide a broad portfolio of diabetes medicines, and our diabetes alliance remains strong," said Enrique Conterno, president of Lilly Diabetes. "There is no group of patients with whom Lilly has a deeper history than those impacted by diabetes. If approved, this basal insulin analog will be an important addition to the Lilly portfolio as we work to provide a broad portfolio of diabetes medicines to our customers."

If the Phase III trials for LY2605541 are successful, Lilly could submit its novel basal insulin analog to regulatory authorities as early as 2014, as previously communicated.
About Diabetes

An estimated 371 million people[1] worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.[2]

Boehringer Ingelheim and Eli Lilly and Company

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on four pipeline compounds representing several of the largest treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com .

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act with social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com .
About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com .

About Lilly Diabetes

Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com .

This press release contains forward-looking statements about Lilly's basal insulin LY2605541 in Phase III clinical trial development. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that LY2605541 will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

*LY2605541 is an investigational agent.   Its efficacy and safety have not been finally established.
CONTACT:
Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: +1-317-651-9116
Ute E Schmidt
Boehringer Ingelheim GmbH
Email:press@boehringer-ingelheim.com
Phone: +49-(6132)-77-97296
REFERENCES
1.   International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012 Update.
2.   International Diabetes Federation. Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes . Accessed on: August 2, 2012.
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO )

Latest Press Release

H.B. Fuller Reports Fourth Quarter and Fiscal Year 2018 Results

H.B. Fuller Company (NYSE: FUL) today reported financial results for the fourth quarter and fiscal year ended Dec. 1, 2018. Items of Note for Fourth Quarter 2018: - Cash flow from operations of $146 million up versus $70 million in the fourth quarter...

A celebration of love under the star at Royal Orchid Sheraton Hotel Towers

Royal Orchid Sheraton Hotel & Towers invites you and your special one to spend a dreamy and picture-perfect evening of the year in our romantic dining setting and take in the sight of an illuminated river, on this 14th February for your unforgettable...

Photo Release: Merit Making Ceremony 2019

Management executives and staff members of two Centara resorts located in Pattaya, led by Metta Boonyaritipong, Hotel Manager of Centara Pattaya Hotel and Centara Nova Hotel & Spa Pattaya joined together to making merit ceremony for 2019 New Year....

Investing in the Rule of Law for a Better Future Thailand Institute of Justice (TIJ)

Investing in the Rule of Law for a Better Future Thailand Institute of Justice (TIJ) and Harvard Law School joined hands to enhance the rule of law and sustainable development through innovation and technology In the ever-changing world, the rule of...

FEAST ON EXTRAVAGANT CULINARY TREASURES OF JAPAN AT HAGI JAPANESE RESTAURANT, CENTARA GRAND HUA HIN

Well-regarded as locals' favorite haunt for tempting Japanese cuisine, Hagi Japanese restaurant at Centara Grand Hua Hin makes better dining vibes this season, adding to the already extravagant all-you-can-eat "Culinary Treasures of Japan" with a variety...

Related Topics